ArticleStem cell reports2018
Immunological Properties of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells.
Article in Stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Immunosuppression in stem cell clinical trials of neural and retinal cell types: A systematic review.PloS one · 2024Pooled it
- A Systematic Review on Transplantation Studies of the Retinal Pigment Epithelium in Animal Models.International journal of molecular sciences · 2020Pooled it
- Safe CNV removal is crucial for successful hESC-RPE transplantation in wet age-related macular degeneration.Stem cell reports · 2025Trial
- Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration.Stem cell reports · 2022Trial
- Single Cell Transcriptomics and Surface Protein Expression Reveal Distinct Cellular and Molecular Phenotypes in Human RPESC-RPE and PSC-RPE.bioRxiv : the preprint server for biology · 2026Article
- PD-L1 Promotes Immunological Tolerance and Enhances Visual Protection of hESC-RPE Grafts in Retinal Degeneration.Cell proliferation · 2025Article
- Stem Cell Therapies in Canine Cardiology: Comparative Efficacy, Emerging Trends, and Clinical Integration.Biomolecules · 2025Review
- 3D Bioprinting of Cellular Therapeutic Systems in Ophthalmology: from Bioengineered Tissue to Personalized Drug Delivery.Current ophthalmology reports · 2025Review
- Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells.Communications medicine · 2024Article
- Advancements in Human Embryonic Stem Cell Research: Clinical Applications and Ethical Issues.Tissue engineering and regenerative medicine · 2024Review
- Article
- Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI Town Hall report.Stem cell research & therapy · 2023Article
- Oxidative stress and mitochondrial transfer: A new dimension towards ocular diseases.Genes & diseases · 2022Review
- Retinal Cell Transplantation, Biomaterials, and In Vitro Models for Developing Next-generation Therapies of Age-related Macular Degeneration.Stem cells translational medicine · 2022Review
- Cell maturation influences the ability of hESC-RPE to tolerate cellular stress.Stem cell research & therapy · 2022Article
- Where Are We with RPE Replacement Therapy? A Translational Review from the Ophthalmologist Perspective.International journal of molecular sciences · 2022Review
- Corneal epithelial differentiation of human pluripotent stem cells generates ABCB5Stem cell research & therapy · 2021Article
- Peptide-based immunotherapy against oxidized elastin ameliorates pathology in mouse model of smoke-induced ocular injury.Experimental eye research · 2021Article
- Association of Blastocystis ST6 with higher protease activity among symptomatic subjects.BMC microbiology · 2021Article
- Localized Structural and Functional Deficits in a Nonhuman Primate Model of Outer Retinal Atrophy.Investigative ophthalmology & visual science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration is caused by dysfunction and loss of retinal pigment epithelium (RPE) cells, and their transplantation may rescue visual functions and delay disease progression. Human embryonic stem cells (hESCs) may be an unlimited source of RPE cells for allotransplantation. We analyzed the immunomodulatory properties of hESC-derived RPE (hESC-RPE) cells, and showed that they inhibited T cell responses. Co-culture experiments showed that RPE cells inhibited interfon-γ secretion and proliferation of activated T cells. Furthermore, hESC-RPE cells enhanced T cell apoptosis and secretion of the anti-inflammatory cytokine interleukin-10 (IL-10). In addition, RPE cells altered the expression of T cell activation markers, CD69 and CD25. RPE cells transplanted into RCS rats without immunosuppression survived, provided retinal rescue, and enhanced IL-10 blood levels. Our data suggest that hESC-RPE cells have immunosuppressive properties. Further studies will determine if these properties are sufficient to alleviate the need for immunosuppression therapy after their clinical allotransplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.